Immune modulators with defined molecular targets: Cornerstone to optimize rational vaccine design

Advances in Experimental Medicine and Biology

Volumn 655, Issue , 2009, Pages 171-188

  Ebensen, Thomas ^b   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; B7 ANTIGEN; BACTERIAL TOXIN; CD134 ANTIGEN; CD1D ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CHOLERA TOXIN; CYCLIC GMP; CYTOKINE; ESCHERICHIA COLI ENTEROTOXIN; FREUND ADJUVANT; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 12; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; ANTIGEN; IMMUNOLOGIC FACTOR; LIGAND; SUBUNIT VACCINE; TOLL LIKE RECEPTOR; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; BURNING SENSATION; CELL COMPOSITION; CELL WALL; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; EDEMA; EROSION; ERYTHEMA; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; NATURAL KILLER T CELL; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; TH2 CELL; VACCINATION; VACCINE PRODUCTION; VIRUS INFECTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; COMMUNICABLE DISEASE; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; INFECTION CONTROL; METABOLISM; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG DESIGN; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LIGANDS; MODELS, BIOLOGICAL; TOLL-LIKE RECEPTORS; VACCINES; VACCINES, SUBUNIT;

EID: 77955495956     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1132-2_13     Document Type: Article

References (158)

1. Agrawal S. Agrawal A. Doughty B et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen, activated protein kinase and c-Fos,J Immunol 2003; 171(10):4984-9. (Pubitemid 37432777)
2. Athman R. Philpott D. Innate immunity via Toll-like receptors and Nod proteins . Cure Opin Microbiol 2004 ; 7(1) :25-32. (Pubitemid 38223951)
3. Dziarski R. Gupta D. Peptidoglycan recognition in innate immunity. J Endotoxin Res 2005: 11(5) :304-10. (Pubitemid 41556039)
4. Meylan E. Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006: 442(7098):39-44. (Pubitemid 44064203)
5. Scott AM, Saleh M. The inllammatory caspases: guardians against infections and sepsis. Cell Death Differ 2007: 14(1):23-31. (Pubitemid 44911891)
6. Dutton RW. In vitro studies of immunological responses of lymphoid cells. Adv Immunol 1967: 6:253-336.
7. Unanue ER. Askonas BA. The immune response of mice to antigen in macrophages. Immunology 1968; 15(2):287-96.
8. Buchan GS. Young SL. Lockhart EA et al. Targeting early events in T-cell activation to construct improved vaccines. Mol Immunol 2000: 37(9) :545-52. (Pubitemid 32001696)
9. Allison AC. Immunological adjuvants and their modes of action. Arch Immunol Ther Exp (Warsz) 1997: 45(2 -3):141-7. (Pubitemid 127513134)
10. Vajdy M. Srivastava I, Polo J et al. Mucosal adjuvants and delivery systems for prorein-, DNA- and RNA-based vaccines. Immunol Cell Biol 2004: 82(6) :617-27. (Pubitemid 39563963)
11. Honma K, Abraham JL. Chiyotani K et al. Proposed criteria for mixed-dust pneumoconiosis: Definition, descriptions and guidelines for pathologic diagnosis and clinical correlation . Hum Pathol 2004; 35(12) :1515-23. (Pubitemid 40017992)
12. Schmidt CS, Morrow WJ, Sheikh NA. Smart adjuvants. Expert Rev Vaccines 2007: 6(3) :391-400. (Pubitemid 46911602)
13. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 2006: 24 Suppl. 2:S226-9.
14. Ott G. Barchfeld GL. Chernoff D et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995; 6:277-96.
15. Podda A. Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003: 2(2):197-203.
16. Patel P, Salapatek AM. Pollinex Qattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006: 5(5) :617-29. (Pubitemid 46021044)
17. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007: 6(2) :133-40. (Pubitemid 46607449)
18. Persing DH. Coler RN. Lacy MJ et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002: 10(10 Suppl):S32-7.
19. De Vendittis E. Palumbo G. Parlato G et al. A fluorimetric method for the estimation of the critical micelle concentration of surfactants. Anal Biochem 1981: 115(2) :278-86.
20. Petrovsky N. Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82(5) :488-96. (Pubitemid 39421058)
21. HolmgrenJ. Adamsson J, Anjuere F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA . Immunol Lett 2005: 97(2) :181-8. (Pubitemid 40326949)
22. Mesa C. Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 2004: 82(6) :644-50. (Pubitemid 39563965)
23. O'Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 1997: 3(2):69-75. (Pubitemid 28095801)
24. Hisert KB. MacCoss M, Shiloh MU et al. A glutamate-alanine-leucine (EAL) domain protein of Salmonella controls bacterial survival in mice, antioxidant defence and killing of macrophages: role of cyclic diGMP. Mol Microbiol 2005: 56(5) :1234-45. (Pubitemid 40756007)
25. O'Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 1998: 50(1) :1-10.
26. Kuroda Y, Nacionales DC. Akaogi J et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharrnacother 2004; 58(5) :325-37. (Pubitemid 38759732)
27. Mellerup MT. Hahn GW, Poulsen LK et al. Safety of allergen-specific immunotherapy, Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30(10) :1423-9.
28. Goswami AK. Mahajan RK. Nath R et al. How safe is 1% alum irrigation in controlling intractable vesical hemorrhage ? J Urol 1993; 149(2):264-7. (Pubitemid 23097569)
29. Graham BS. Keefer MC. McElrath MJ et al. Safety and immunogenicity of a candidate HIV-l vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996: 125(4) :270-9. (Pubitemid 126449271)
30. Ruf BR. Colberg K, Frick M et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004: 32(4) :191-8. (Pubitemid 39070597)
31. Weeratna RD, McCluskie MJ, XU Y et al. CpG DNA induces stronger immune responses with less toxicitythan other adjuvants. Vaccine 2000: 18(17):1755-62. (Pubitemid 30122837)
32. Fujihashi K, Koga T, van Ginkd FW et al.A dilemma for mucosal vaccination: efficacy versus toxicity usingenterotoxin-based adjuvants. Vaccine 2002: 20(19-20):2431-8. (Pubitemid 34615580)
33. van Ginkd FW;Jackson RJ, Yuki Y et al. Cutting edge: the mucosal adjuvant choleratoxin redirects vaccine proteins into olfactory tissues. J Immunol 2000: 165(9):4778-82.
34. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996: 13(1-2):1-55. (Pubitemid 26300177)
35. COX JT, Petry KU, Rylander E et al. Using imiquimod for genital warts in female patients. J Womens Health (Larchmt) 2004; 13(3):265-71. (Pubitemid 38660523)
36. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58(1):68-89.
37. Kirk DD, Rempel R, Pinkhasov J et al. Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines. Expert Opin Biol Ther 2004: 4(6):947-58. (Pubitemid 38843231)
38. Kensil CR, Wu JY, Soltysik S. Strucrural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 1995: 6:525-41.
39. McCluskie MJ, Weeratna RD. Novel adjuvant systems. Curr Drug Targets Infect Disord 2001; 1(3):263-71.
40. Morein B, Bengtsson KL. Immunomodulation by iscoms, immune stimulating complexes. Methods 1999; 19(1):94-102. (Pubitemid 29497758)
41. Kersten G, Hirschberg H. Antigen delivery systems. Expert Rev Vaccines 2004: 3(4):453-62. (Pubitemid 39061710)
42. Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J Leukoc Biol 1998; 64(6):713-23. (Pubitemid 28555383)
43. Moser C,, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003; 2(2):189-96. (Pubitemid 36559924)
44. Felnerova D, Virec JF, Gluck R, et al.Liposomes and virosomes as delivery systems for antigens, nucleic acidsand drugs. Curr Opin Biotechnol 2004: 15(6):518-29. (Pubitemid 39551004)
45. Bungener L, Huckriede A, Wilschut J et al. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci Rep 2002: 22(2):323-38. (Pubitemid 35222739)
46. Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes, Curr Drug Deliv 2005: 2(4):395-400. (Pubitemid 41277771)
47. Kirkley JE, Goldstein AL, Naylor PH. Adjuvant propertiesof montanide CSA720 with a recombinant HIV P17 gagprotein and syntheticpeptide antigens. Scand J Immunol 1996: 43(4):431-8. (Pubitemid 26106154)
48. Dupuis L, Ascarateil S, Aucoururier J et al. SEPPIC vaccine adjuvants for poultry.Ann NY Acad Sci 2006; 1081:202-5. (Pubitemid 44968774)
49. Aucoururier J, Dupuis L, Deville S et al. Monranide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002: 1(1):111-8. (Pubitemid 36686885)
50. Charoenvit Y, Goel N, Whelan M et al. CEL-l000-a peptide with adjuvant activity for Th1 immune responses. Vaccine 2004; 22(19):2368-73. (Pubitemid 38757331)
51. Charoenvit Y, Brice GT,Bacon D et al.A small peptide(CEL-1000) derived fromthe beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemorher2004: 48(7):2455-63. (Pubitemid 38823410)
52. Allan E, Wren BW Genes to genetic immunization: identification of bacterial vaccine candidates. Methods 2003; 31(3):193-8. (Pubitemid 37162791)
53. Workman P. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Cure Cancer Drug Targets 2001: 1(1):33-47. (Pubitemid 33772173)
54. Schneider J, Gilbert SC, Hannan CM et al. Induction of CD8+ T-cells usingheterologous prime-boost immunisation strategies. Immunol Rev 1999; 170:29-38. (Pubitemid 29490742)
55. Hernmi H, Kaisho T, Takeuchi O et al.Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3(2):196-200. (Pubitemid 34141451)
56. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006: 27(1):49-55. (Pubitemid 43083564)
57. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006: 124(4):783-801. (Pubitemid 43261452)
58. Schwarz K, Storni T, Manolova V et al. Role of Toll-like receptors in costimulating cytotoxic T-cell responses. Eur J Immunol 2003; 33(6):1465-70. (Pubitemid 36790406)
59. Ishii KJ, Coban C, Akira S. Manifold mechanisms of toll-like receptor-ligand recognition. J Clin Immunol 2005; 25(6):511-21. (Pubitemid 43011743)
60. Chisholm D, Libet L, Hayashi T et al. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol 2004; 113(3):448-54. (Pubitemid 38338949)
61. Johansen P, Senti G, Martinez Gomez JM et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005: 35(12):1591-8.
62. Hessel EM, Chu M, Lizcano JO et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005; 202(11) :1563-73. (Pubitemid 41746602)
63. Dabbagh K, Lewis DB. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003; 16(3):199-204. (Pubitemid 36677312)
64. Gangloff SC, Guenounou M. Toll-like receptors and immune response in allergic disease. Clin Rev Allergy Immunol 2004; 26(2) :115-25. (Pubitemid 38813592)
65. Patel M, Xu D, Kewin P et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T-cells. J Immunol 2005; 174(12):7558-63. (Pubitemid 40806259)
66. Liu H, Komai-Koma M, Xu D et al. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulator y T-cells, Proc Natl Acad Sci USA 2006; 103(18) :7048-53.
67. Spohn R, Buwitt-Beckmann U, Brock R et al. Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships. Vaccine 2004; 22(19) :2494-9. (Pubitemid 38757349)
68. Rharbaoui F, WestendorfA, Link C et al. The Mycoplasma-derived macrophage-activaring 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun 2004; 72(12) :6978-86. (Pubitemid 39552366)
69. Katz J, Zhang P, Martin M et al, Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun 2006; 74(5):2809-16. (Pubitemid 43672990)
70. Mitsunari M, Yoshida S, Shoji T et al. Macrophage-activating lipopeptide-2 induces cyclooxygenase-2 and prostaglandin E(2) via toll-like receptor 2 in human placental trophoblas T-cells. J Reprod Immunol 2006; 72(1 -2):46-59. (Pubitemid 44692307)
71. Espuelas S, Roth A, Thumann C et al. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol Immunol 2005; 42(6) :721-9. (Pubitemid 40386714)
72. Borsutzky S, Fiorelli V, Ebensen T et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 2003; 33(0014-2980 VI-33 IP -6 DP-2003):1548-56. (Pubitemid 36790415)
73. Azuma I, SeyaT. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1(7):1249-59. (Pubitemid 32522979)
74. Skidmore BJ, Chiller JM, Morrison DC et al. Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitogenic , adjuvant and immunogenic activities. J Immunol 1975; 114(2 pt 2):770-5.
75. Skidmore BJ, Chiller JM, Weigle WO et al. Immunologic properties of bacterial lipopo lysaccharide (LPS). IV. Cellular basis of the unresponsiveness of C3H/HeJ mouse spleen cells to LPS-induced mitogenesis. J Immunol 1977; 118(1) :274-81. (Pubitemid 8028539)
76. Skidmore BJ, Chiller JM, Weigle WO et al. Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS. J Exp Med 1976; 143(1) :143-50.
77. Skidmore BJ, Morrison DC, Chiller JM et al. Immunologic properties of bacterial lipopolysaccharide (LPS). II. The unresponsiveness ofC3H/HeJ Mouse spleen cells to LPS-induced mitogenesis is dependent on the method used to extract LPS. J Exp Med 1975; 142(6):1488-508.
78. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/1OScCr mice: mutations in Tlr4 gene. Science 1998; 282(5396) :2085-8. (Pubitemid 29001265)
79. Mara-Hare V. Cekic C, Martin M et al, The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist ofTLR4. Science 2007; 316(5831) :1628-32. (Pubitemid 46982038)
80. Baldridge JR , McGowan P, Evans JT et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monorherapeutic agents. Expert Opin Biol Ther 2004; 4(7) :1129-38. (Pubitemid 38937554)
81. Siner M, Pocidalo JJ. Are immuno modulators capable to improve the activity of nucleoside antiretroviral agents? J. Pathol Biol (Paris) 1993; 41(8 Pt 2):794-8.
82. Robinson RA. DeVita VT. Levy HB et al. A phase I-II trial of multiple-dose polyribolnosic-polyribocytidylic acid in parieonrs with leukemia or solid rumors. J Natl Cancer Inst 1976; 57(3):599-602.
83. Adams M. Navabi H, Jasani B et aL Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically nontoxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 2003 30; 21(7-8):787-90.
84. Huleatt JW, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007; 25(4) :763-75. (Pubitemid 44856106)
85. Honko AN, Sriranganathan N, Lees CJ et al Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006; 74(2) :1113-20. (Pubitemid 43185549)
86. Szabo C. Role of flagellin in the pathogenesis of shock and acute respiratory distress syndrome: therapeutic opportunities. Crit Care Med 2003; 31(1 Suppl):S39-45 . (Pubitemid 36143476)
87. Langford MP. Chen D. Gosslee J et al. Intracameral toxicity of bacterial components muramyl dipeptide and staurosporine: ciliary cyst formation, epithelial cell apoptosis and necrosis. Cutan Ocul Toxicol 2006; 25(2) :85-101. (Pubitemid 43879618)
88. Saha S. Takeshita F. Matsuda T et al. Blocking of the TLR5 Activation Domain Hampers Protective Potential of Flagellin DNA Vaccine.J Immunol 2007; 179(2) :1147-54.
89. Wu JJ. Huang DB. Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004; 64(2):79-83. (Pubitemid 39446130)
90. Gupta AK. Browne M. Bluhm R. Imiquimod: a review.J Cutan Med Surg 2002; 6(6) :554-60. (Pubitemid 36091502)
91. Schonberger O. Hirst TR. Pines O. Targeting and assembly of an oligomeric bacterial enrerotoxoid in the endoplasmic reticulum of Saccharomyces cerevisiae. Mol Microbiol 1991; 5(11) :2663-71. (Pubitemid 21895999)
92. Syed TA. A review of the applications of imiquimod: a novel immune response modifier. Expert Opin Pharmacother 2001; 2(5):877-82. (Pubitemid 32750343)
93. Thomsen LL. Topley P. Daly MG et al. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by panicle-mediated immunotherapeutic delivery. Vaccine 2004; 22(13-14):1799-809. (Pubitemid 38447228)
94. Carrington AC. Secombes CJ, A review of CpGs and their relevance to aquaculture. Vet Immunol Immunopathol 2006; 112(3-4) :87-101. (Pubitemid 43975152)
95. Jurk M. Hell F. Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3(6):499. (Pubitemid 34669818)
96. Ioannou XP. Griebel P, Mena A et al. Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev 2003; 13(3):157-67.
97. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000 ; 44(2-3) :119-34.
98. Gurunathan S. Klinman DM. Seder RA. DNA Vaccines: Immunology. Application and Optimization. Annu Rev Immunol 2000; 18(1):927-74. (Pubitemid 30365401)
99. Dalpke A. Zimmermann S. Heeg K. CpG DNA in the prevention and treatment of infections. BioDrugs 2002; 16(6):419-31. (Pubitemid 36020852)
100. Arce S. Nawar HF. Russell MW et al. Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation and activation of lymphoid cells. Infect Immun 2005; 73(5):2718-27. (Pubitemid 40570337)
101. Fukuta S. Magnani JL. Twiddy EM et al. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa and LT-IIb. Infect Immun 1988; 56(7) :1748-53.
102. Johnson SM. Lerche NW; Pappagianis D et al. Antigenicity, safety and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus maques (Macaca fascicularis). Ann NY Acad Sci 2007.
103. Schnitzler AC. Burke JM. Wetzler LM. Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells. Infect Immun 2007; 75(6) :3150-9. (Pubitemid 46870201)
104. Kawamura YI. Kawashima R. Shirai Y et al. Cholera toxin activates dendritic cells through dependence on GMl-ganglioside which is mediated by NF-κB translocation. Eur J Immunol 2003; 33(11):3205-12. (Pubitemid 37428353)
105. Williams NA. Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic. Int J Med Microbiol 2000; 290(4-5):447-53.
106. Pizza M. Giuliani MM. Fontana MR et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19(17-19):2534-41. (Pubitemid 32234269)
107. Plant A. Williams NA. Modulation of the immune response by the cholera-like enterotoxins. Curr Top Med Chem 2004; 4(5):509-19. (Pubitemid 38832734)
108. Lalazar G., Preston S., Zigmond E., et al. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006; 6(11): 1249-1253. (Pubitemid 44697104)
109. Chen YG. Choisy-Rossi CM. Holl TM et al. Activated NKT cells inhibit auto immune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005; 174(3) :1196-204.
110. Van Kaer L. Natural killer T-cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 2004; 82(3):315 -22. (Pubitemid 38870026)
111. Yamamura T. Miyamoto K. Illes Z et al. NKT cell-stimulating synthetic glycolipids as potential thera peutics for autoimmune disease. Curr Top Med Chem 2004; 4(5) :561-7. (Pubitemid 38832739)
112. Parekh VV. Singh AK. Wilson MT et al. Qantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and bera-anomeric glycolipids.J Immunol 2004; 173(6):3693-706. (Pubitemid 39280730)
113. Gonzalez-Aseguinolaza G. Van Kaer L. Bergmann CC et al. Natural killer T-cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.J Exp Med 2002; 195(5):617-24. (Pubitemid 34461506)
114. Nishimura T. Kitamura H. Iwakabe K et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T-lymphocytes. Int Immunol 2000; 12(7):987-94. (Pubitemid 30601366)
115. Sakai T. Ehara H, Koezuka Y. Synthesis of NBD-alpha-galactosylceramide and its immunologic properties. Org Lett 1999; 1(3):359-61.
116. Yamauchi A, Dai SY, Nakagawa R et al. [Galectin-9 induces maturation of human monocyte-derived dendritic cellsJ. Nihon Rinsho Meneki Gakkai Kaishi 2005; 28(6):381-8.
117. Youn HJ, Ko SY,Lee KA et al,A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 2007; 25(28) :5189-98.
118. Sakaue G, Hiroi T. Naltagawa Y et al, HIV mucosalvaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003; 170(1):495-502. (Pubitemid 36026176)
119. Ebensen T, Link C, Riese P et al. A Pegylated Derivative of {alpha}-Galactosylceramide Exhibits Improved Biological Properties. J Immunol 2007; 179(4) :2065-73.
120. Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2002; 2(5) :513-24. (Pubitemid 34716734)
121. Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23 and IL-27. Arch Immunol Ther Exp (Warsz) 2006; 54(1) :15-24. (Pubitemid 44124218)
122. Margolin KA. Interleukin -2 in the treatment of renal cancer. Semin Oncol 2000; 27(2):194-203.
123. Shanmugham LN, Petrarca C, Frydas S et al. IL-15 an immunoregulatory and anti-cancer cyrokine. Recent advances.J Exp Clin Cancer Res 2006; 25(4) :529-36. (Pubitemid 46166767)
124. Yan L, Anderson GM, DeWitte M et al. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006; 42(6):793-802.
125. Flanagan K, Kaufman HL. Chernokines in tumor immuno therapy. Front Biosci 2006; 11:1024-30.
126. Slettenaar VI. Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006; 58(8) :962-74. (Pubitemid 44780906)
127. Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines 2007; 6(2) :267-83. (Pubitemid 46607460)
128. Anton P, Kirchner H. Jonas U et al. Cyrokines and tumor vaccination. Cancer Biother Radiopharm 1996; 11(5):315-8.
129. Parmiani G, Arienti F, Sule-Suso J et al. Cyrokine-based gene therapy of human tumors. An overview. Folia Biol (Praha) 1996; 42(6) :305-9. (Pubitemid 127586396)
130. Villinger F. Cyrokines as clinical adjuvants: how far are we? Expert Rev Vaccines 2003; 2(2) :317-26. (Pubitemid 36564801)
131. Ellouz F, Adam A, Ciorbaru R et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974; 59(4):1317-25.
132. Inohara N, Ogura Y,Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohns disease. J Biol Chern 2003; 278(8) :5509-12. (Pubitemid 36800790)
133. Uehori J, Fukase K, AkazawaT et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2 /TLR4 activation. J Immunol 2005; 174(11) :7096-103. (Pubitemid 40705675)
134. Ferwerda G, Girardin SE, Kullberg BJ et al, NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 2005 ; 1(3):279-85.
135. Sevcik J, Masek K. The interaction of immunomodulatory muramyl dipeptide with peripheral 5-HT receptors: overview of the current state. Int J Immunopharmacol 1999; 21(3):227-32. (Pubitemid 29142444)
136. Jiang ZH, Koganry RR. Synthetic vaccines: the role of adjuvants in immune targeting. Curr Med Chem 2003; 10(15) :1423-39.
137. O'Reilly T, Zak O. Enhancement of the effectiveness of antimicrobia l therapy by muramyl pept ide imrnunomodularors. Clin Infect Dis 1992; 14(5):1100-9.
138. Kaliuzhin OV. [Muramyl dipeptide derivativesin experimental and clinical use J. Zh Mikrobiol Epidemiol Immunobiol 1998:104-8.
139. Hui GS. Liposomes, muramyl dipeptide derivatives and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Am J Trop Med Hyg 1994; 50(4 Suppl):41-51. (Pubitemid 24158403)
140. Becker PD, Norder M. Guzman CA et al. Immune modulator adamanrylamide dipeptide stimulates efficient major histocompatibility complex class l-restricted responses in mice. Clin Vaccine Immunol 2007; 14(5):538-43.
141. Becker PD, Bertot GM, SoussD et al. Intranasal vaccination with recombinant outer membrane protein CD and adarnanrylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhal is in an experimental murine model. Infect Immun 2007 ; 75(4) :1778-84. (Pubitemid 46559445)
142. Bertot GM, Becker PD, Guzman CA et al. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 2004; 189(7):1304-12. (Pubitemid 38457257)
143. Becker PD, Corral RS. Guzman CA et al. Adamanrylamide dipeptide as effective immunoadjuvantin rabbits and mice. Vaccine 2001; 19(32) :4603-9. (Pubitemid 32800741)
144. Subauste CS. CD154 and type-I eytokine response: from hyper IgM syndrome to human immunodeficiency virus Infecdon.J Infect Dis 2002; 185 Suppl. I:S83-9. (Pubitemid 34142833)
145. Barr TA. Carlring J , Heath AW. Costimulatory agonisrs as immunological adjuvants. Vaccine 2006; 24( 17):3399-407.
146. Cairing J. Barr T, Heath AW.Adjuvanticity of anti-cD4Oin vaccine developrnenr, Curr Opin Mol Ther 2005; 7(1):73-7.
147. Ahlers JD, Bdyakov IM, Berzofsky JA. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacyof HIV vaccines. Curr Mol Med 2003; 3(3):285-301. (Pubitemid 36443226)
148. Sugamura K, Ishii N. Weinberg AD. Therapeutic targeting of the effector T-cdl costimulatory molecule OX4O. Nat Rev Immunol 2004; 4(6) :420-31. (Pubitemid 38745554)
149. Dohring C. Angman L, Spagnoli G et al. T-hdper- and accessory-cell- independent cytotoxic responses to human tumor cells eransfecred with a B7 rerroviral vector, Int J Cancer 1994; 57(5):754-9. (Pubitemid 24201371)
150. Chen L. McGowan P, Ashe S et al. B7-1/CD80-rransduced tumor cells dicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 1994; 54(20):5420-3. (Pubitemid 24336035)
151. Chen L. McGowan P, Ashe S et al. Tumor immunogenicity determines the effeer ofB7 costimulation on Tvcell-medlaced tumor immunity. J Exp Med 1994; 179(2):523-32.
152. Kalus RM. Kantor JA. Gritz L et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999; 17(7-8):893-903. (Pubitemid 29074744)
153. Romling U, Amikam D. Cyclic di-GMP as a second messenger. Curr Opin Microbiol 2006; 9(2):218-28.
154. Romling U. Gomdsky M. Galperin MY. C-di-GMP: the dawning of a novd bacterial signalling system. Mol Microbiol 2005; 57(3):629-39. (Pubitemid 41025947)
155. Karaolis DK. Cheng K, Lipsky M et al. 3', 5'-Cyclic diguanylic acid (c-di-GMP ) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Blochern Biophys Res Commun 2005; 329(1):40-5. (Pubitemid 40255417)
156. Ebensen T, Schulze K. Riese P et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 2007; 25(8):1464-9. (Pubitemid 46074291)
157. Ebensen T, Schulze K. Riese P et al. The bacterial second messenger cdiGMP exhibits promising activity as mucosal adjuvant. Clin Vaccine Immunol 2007; 14(8):952-8.
158. Karaolis DK, Means TK, Yang D et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 2007; 178(4):2171-81. (Pubitemid 46233415)